Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

The Multiple Myeloma Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Gold) and Legend Biotech (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.

Share this video  

EHA 2022 | A comparison of bispecific antibodies emerging in multiple myeloma

Monique Minnema • 11 Jun 2022
EHA 2022
Multiple Myeloma Antibodies Talquetamab
MonumenTAL-1

Monique Minnema, MD, PhD, University Medical Center Utrecht, Utrecht, Netherlands, gives a brief overview of bispecific antibodies emerging for the treatment of multiple myeloma, highlighting the main differences between BCMA-targeting and GPRC5D-targeting agents. This interview took place at the European Hematology Association (EHA) Congress 2022 held in Vienna, Austria.

More from Monique Minnema

Bing-Neel syndrome: a rare form of Waldenström’s macroglobulinemia 2:25
Bing-Neel syndrome: a rare form of Waldenström’s macroglobulinemia
Monique Minnema • 13 Nov 2024
Treating Bing-Neel syndrome: chemotherapy and BTK inhibitors 4:20
Treating Bing-Neel syndrome: chemotherapy and BTK inhibitors
Monique Minnema • 13 Nov 2024
Diagnosing Bing-Neel syndrome using MRI and lumbar puncture 1:27
Diagnosing Bing-Neel syndrome using MRI and lumbar puncture
Monique Minnema • 13 Nov 2024
Advice for physicians when managing bispecific antibody treatment for patients with myeloma 0:47
Advice for physicians when managing bispecific antibody treatment for patients with myeloma
Monique Minnema • 2 Jun 2024

Related Videos

The FDA approval of daratumumab for high-risk smoldering myeloma based on the AQUILA trial 10:22
The FDA approval of daratumumab for high-risk smoldering myeloma based on the AQUILA trial
Peter Voorhees • 19 Nov 2025
Promising approaches being explored in high-risk myeloma & trials to look out for 2:11
Promising approaches being explored in high-risk myeloma & trials to look out for
Sham Mailankody • 24 Oct 2025
The value of extensive profiling in single-arm trials for high-risk myeloma 2:39
The value of extensive profiling in single-arm trials for high-risk myeloma
Martin Kaiser • 24 Oct 2025
How is the definition of high-risk myeloma evolving in the era of CAR T-cell therapy? 2:35
How is the definition of high-risk myeloma evolving in the era of CAR T-cell therapy?
Sham Mailankody • 24 Oct 2025
The content of VJHemOnc is intended for healthcare professionals